Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.3452W HIGH $30.00
Volume
379.73 K
Value Traded
9.91 M
Short % Float
12.85%
-6.05%Week
+7.06%1 Month
-0.85%3 Month
+44.21%6 Month
-5.71%5 Year
-5.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.53 B
EPS (TTM)
-2.52
P/E Ratio
-
Ent. Value
1.41 B
Total Shares
59.56 M
Float Shares
24.30 M
Insiders
59.20%
Institutions
46.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KMTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Kestra Medical Technologies, Ltd.
Past FDA Catalysts and PDUFA Decisions
How KMTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Kestra Medical Technologies, Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every KMTS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ASSURE WCD | sudden cardiac death prevention | 2025-11-10 | The ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) enrolled 21,612 patients and demonstrated strong effectiveness in preventing sudden cardiac death, confirming the device's safety and compliance in real-world use during elevated risk periods.Read More | Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE DeviceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| COHEN RAYMOND WDirector | Sell | -3,330 54,790 held | $29.28 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KMTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.1 % (-50 %) | 7.56 M | 285.00 K | 42.5% ( 85.00 K) |
KMTS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KMTS ranks across every disease it competes in
Competitive Position is a premium feature
See how KMTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKMTS News
KMTSKestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
Kestra Medical Technologies has been awarded a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies for 2026. This recognition highlights the company's rapid growth and innovation in the medical equipment sector, particularly with its ASSURE® WCD product. Kestra aims to expand its Cardiac Recovery System® platform and enhance its market presence.
Read more →KMTSKestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
Kestra Medical Technologies reported a strong financial performance for Q1 FY27, with revenues reaching $31 million, a 60% increase year-over-year. The company also raised its revenue guidance for the fiscal year to $141 million, reflecting confidence in continued growth. However, net losses and operating expenses increased, raising concerns about profitability amidst expansion efforts.
Read more →KMTSKestra Names Daniel Finney Vice President of Research & Development
Kestra Medical Technologies has appointed Daniel Finney as Vice President of Research & Development, succeeding Phillip D. Foshee, Jr. Finney's extensive experience in medical device development is expected to enhance the company's innovation in its Cardiac Recovery System platform. His leadership will focus on integrating AI and real-world insights into product development strategies.
Read more →KMTSKestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
Kestra Medical Technologies, Ltd. will announce its first quarter fiscal 2027 financial results on September 14, 2026. The report will be followed by a conference call at 4:30 p.m. ET, where management will discuss the results. The company specializes in wearable medical devices aimed at improving cardiovascular health.
Read more →KMTSKestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
Kestra Medical Technologies has appointed Curtis Kopf as Senior Vice President of Customer Experience. In this role, he will oversee the patient experience from order approval to therapy completion. Kopf brings extensive experience in customer experience and digital transformation, aiming to enhance patient engagement and operational efficiency through innovative technologies and AI initiatives.
Read more →KMTSKestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
Kestra Medical Technologies has announced a five-year term loan facility worth up to $200 million with Pharmakon Advisors. The financing includes a $75 million initial tranche and options for additional funds based on revenue milestones. This move is expected to enhance Kestra's financial flexibility and support its growth strategies in the wearable medical device sector.
Read more →KMTSKestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Kestra Medical Technologies reported strong financial results for Q4 and FY 2026, with revenues increasing by 66% and 59% respectively. The company achieved a gross margin improvement and provided guidance for FY 2027, expecting a revenue increase of 44%. Despite these positives, Kestra continues to face significant net losses.
Read more →KMTSKestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
Kestra Medical Technologies, a prominent player in wearable medical devices, will report its fourth quarter fiscal 2026 financial results on July 14. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors can access a live and archived webcast of the call.
Read more →KMTS▼ -9.9%on this news
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
Kestra Medical Technologies will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The presentation is scheduled for 2:20 p.m. Pacific Time. Interested individuals can access the live webcast and replay through the company's investor relations website. Kestra aims to improve patient outcomes in cardiovascular disease with its advanced technologies.
Read more →KMTSKestra Showcases Accelerated Innovation at HRS 2026
Kestra Medical Technologies will exhibit its Cardiac Recovery System at the Heart Rhythm Society's annual meeting in Chicago. The company aims to demonstrate the benefits of its ASSURE WCD platform, which integrates therapy and clinical insights for managing sudden cardiac arrest risk. An updated algorithm, recently approved by the FDA, will also be showcased to enhance patient care.
Read more →KMTSKestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
Kestra Medical Technologies has been awarded the 2026 USA TODAY Top Workplaces award, recognizing its commitment to employee engagement and a positive work culture. CEO Brian Webster highlighted the importance of collaboration and innovation in developing life-saving technologies. The award is based on confidential feedback from team members, reflecting their trust in the organization.
Read more →KMTSKestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
Kestra Medical Technologies has been named a finalist for the 'Deal of the Year' at the 2026 GeekWire Awards, recognizing its successful 2025 IPO. This achievement underscores the company's growth and commitment to innovation in the cardiac care sector. Community voting for the awards is open until April 16, 2026, with winners to be announced on May 7, 2026.
Read more →KMTS▲ +9.8%on this news
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies reported strong financial results for Q3 FY26, with a 63% increase in revenue to $24.6 million and an expanded gross margin of 52.6%. The company raised its FY26 revenue guidance to $93 million, reflecting robust growth and market share gains. However, it also reported a higher net loss and adjusted EBITDA loss compared to the previous year.
Read more →KMTSKestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
Kestra Medical Technologies, a prominent player in wearable medical devices, will report its third quarter fiscal 2026 financial results on March 17. A conference call is scheduled for 4:30 p.m. ET, allowing investors to engage with management. The company focuses on improving patient outcomes in cardiovascular disease.
Read more →KMTS▼ -5.9%on this news
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
Kestra Medical Technologies has announced a strategic collaboration with Biobeat Technologies to enhance diagnostic insights for patients using the ASSURE Wearable Cardioverter Defibrillator. The partnership includes a $5 million investment from Kestra into Biobeat's Series B financing. This collaboration aims to integrate Biobeat's innovative blood pressure monitoring technology into Kestra's product offerings, potentially improving patient management during cardiac recovery.
Read more →KMTSKestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Kestra Medical Technologies, a digital healthcare company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13. The presentation is aimed at showcasing their advancements in wearable medical devices for cardiovascular disease. Interested parties can access the live webcast through their investor relations website.
Read more →KMTSKestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies has reported its financial results for the second quarter of fiscal 2026, showcasing a revenue increase of 53% year-over-year to $22.6 million. The company has also expanded its gross margin significantly and increased its revenue guidance for the fiscal year. However, despite this growth, the company continues to experience a net loss and a rise in operating expenses. Kestra is focused on executing its strategy aimed at leadership in the wearable defibrillator market.
Read more →KMTS▲ +12.2%on this news
Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies, Ltd. will report its second quarter fiscal 2026 financial results on December 11, 2025. A conference call will follow at 4:30 p.m. Eastern Time, with a live and archived webcast available. The company specializes in wearable medical devices and aims to improve patient outcomes in cardiovascular healthcare.
Read more →KMTS▲ +12.2%on this news
Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
Kestra Medical Technologies, Ltd. announced the pricing of its upsized public offering of 6 million common shares at $23.00 per share, aiming to raise $138 million. The offering is scheduled to close on December 4, 2025, subject to customary conditions. Underwriters have an option for an additional 900,000 shares, underscoring investor confidence. Prominent financial institutions are facilitating the offering, with materials available through SEC filings.
Read more →KMTS▼ -8.5%on this newsshared move
Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares
Kestra Medical Technologies, Ltd. has announced a public offering of 5,500,000 common shares to support its operations and growth. The offering is contingent upon market conditions and includes an option for underwriters to purchase additional shares. Proceeds will be allocated to sales, marketing, and research initiatives. The registration statement for the offering has been filed but is not yet effective.
Read more →About Kestra Medical Technologies, Ltd.
Headquarters3933 LAKE WASHINGTON BLVD NE, KIRKLAND, WA, 98033
BIOPHARMAWATCH ELITE PLUS
Trade the next KMTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime